Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion
Michael Ryskin

Michael Ryskin Analyst Performance

Managing Director at Bank of America

Michael Ryskin is a stock analyst at Bank of America in the medical sector, covering 8 publicly traded companies. Over the past year, Michael Ryskin has issued 6 stock ratings, including buy and hold recommendations. While full access to Michael Ryskin's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Michael Ryskin's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 6 Years
Buy Recommendations
28.57% 4 Buy Ratings
Companies Covered
8 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy28.6%4 ratings
Hold71.4%10 ratings
Sell0.0%0 ratings

Out of 14 total stock ratings issued by Michael Ryskin at Bank of America, the majority (71.4%) have been Hold recommendations, followed by 28.6% Buy.

Exchange Coverage

ExchangePercentageCount
NASDAQ
62.5% of companies on NASDAQ
5 companies
NYSE
37.5% of companies on NYSE
3 companies

Michael Ryskin, an analyst at Bank of America, currently covers 8 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
8 companies
100.0%

Michael Ryskin of Bank of America specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - DRUGS
2 companies
25.0%
MEDICAL INFO SYS
2 companies
25.0%
MEDICAL SERVICES
1 company
12.5%
MED PRODUCTS
1 company
12.5%
MED INSTRUMENTS
1 company
12.5%
MED - OUTP/HM CRE
1 company
12.5%

Michael Ryskin's Ratings History at Bank of America

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Recursion Pharmaceuticals, Inc. stock logo
RXRX
Recursion Pharmaceuticals
2/25/2026Lower Price Target$3.79$6.00Neutral
Zoetis Inc. stock logo
ZTS
Zoetis
2/13/2026Boost Price Target$125.58$140.00Neutral
Schrodinger, Inc. stock logo
SDGR
Schrodinger
12/15/2025Upgrade$18.05$24.00Buy
Revvity Inc. stock logo
RVTY
Revvity
12/15/2025Downgrade$98.80$110.00Neutral
Revvity Inc. stock logo
RVTY
Revvity
9/22/2025Lower Price Target$86.36$99.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
6/25/2025Boost Price Target$67.14$70.00Neutral
Tempus AI, Inc. stock logo
TEM
Tempus AI
5/20/2025Boost Price Target$63.74$68.00Neutral
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
3/3/2025Lower Price Target$3.22$8.00Buy
Tempus AI, Inc. stock logo
TEM
Tempus AI
3/3/2025Boost Price Target$56.18$60.00Neutral
IDEXX Laboratories, Inc. stock logo
IDXX
IDEXX Laboratories
2/4/2025Boost Price Target$469.04$535.00Neutral